NSCLC


Also found in: Acronyms.

NSCLC

non (or cancer).

NSCLC

Non-small cell lung cancer, see there.
References in periodicals archive ?
We are initially focusing on evaluating DS-1062 in patients with advanced NSCLC with potential expansion into other tumor types depending on the results of this early critical test in a study designed to provide evidence supporting unique properties of this particular TROP2 ADC construct, said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo.
Across both NSCLC cohorts, the responders with known PD-(L)1 expression levels were all observed to be low (1-49%) or negative expressors.
This study aimed to evaluate the diagnostic and prognostic values of serum MIC-1 measurement in the early-stage (Stage I and II) NSCLC.
To find novel NSCLC mutations, a research team led by Rebecca S.
What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
1 It is estimated that more than 60% of NSCLC patients showed unresectable advanced disease when they were diagnosed.
According to the researchers, their findings suggest a "transferability" of the malignancy-risk gene signature between breast cancer and NSCLC, a "unique feature not seen in other gene signatures derived for various tumor types.
Tarceva is already approved in Europe for use in advanced or metastatic NSCLC irrespective of a patient's EGFR status both as maintenance therapy immediately after initial chemotherapy and when the disease has progressed following at least one course of chemotherapy.
In the study, researchers compared outcomes for 265 patients with locally advanced NSCLC who received 3-D conformal radiation and concurrent chemotherapy.
With numerous unidentified molecular drivers for NSCLC and a high level of unmet need among NSCLC patients with squamous-cell tumors and KRAS-mutated tumors, there is significant commercial opportunity for innovative new treatments for NSCLC.
While the treatment of metastatic EGFR-mutated NSCLC has significantly improved over the past decade, new treatments are needed that work to overcome resistance associated with current EGFR TKIs, said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo.